7 11

Cited 0 times in

Cited 0 times in

A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group

DC Field Value Language
dc.contributor.author박예원-
dc.contributor.author장종희-
dc.contributor.author안성수-
dc.contributor.author안성수-
dc.date.accessioned2026-01-06T00:47:32Z-
dc.date.available2026-01-06T00:47:32Z-
dc.date.issued2025-12-
dc.identifier.issn1470-2045-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/209772-
dc.description.abstractBackground: The efficacy of resection in IDH-mutant grade 2 gliomas remain controversial since terminology for the extent of resection has been inconsistently applied across studies. We aimed to establish a standardised classification for the extent of resection and assess the association between supramaximal resection and survival across molecular subtypes. Methods: In this international, multicentre, retrospective study, patients aged 18 years and older with newly diagnosed grade 2 IDH-mutant glioma were identified from institutional databases across 16 centres in the USA, Europe, and Asia between between Sept 1, 1993, and May 10, 2024. We used Cox proportional hazard regressions to analyse the associations between residual tumour and progression-free survival and overall survival. Patients were stratified according to a previously postulated classification system based on residual tumour volume. A cohort of patients from UCSF diagnosed between Feb 16, 1998, and Nov 14, 2017, was used for geographically and institutionally independent external validation. Findings: We identified 1391 patients with newly diagnosed IDH-mutant grade 2 gliomas, with a median follow-up of 81 months (95% CI 78-85). 728 patients (379 with astrocytoma and 349 with oligodendroglioma) received no first-line treatment beyond surgery, allowing us to study the isolated effects of resection. Patients with maximal T2-fluid attenuated inversion recovery (T2-FLAIR) resection (class 2; 0-5 cm3 remnant) had superior progression-free and overall survival compared with submaximal T2-FLAIR resection (class 3; 5-25 cm3 remnant) or minimal T2-FLAIR resection (class 4; >25 cm3 remnant), with 10-year survival rates of 82% (95% CI 76-87) versus 75% (62-84) versus 48% (29-65; p<0·0001) and 5-year progression-free survival rates of 44% (38-50) versus 25% (16-34) versus 12% (4-24; p<0·0001), respectively. Resection beyond T2-FLAIR borders (class 1) provided survival benefits, with a 10-year survival rate of 98% (95% CI 92-99) and a 5-year progression-free survival rate of 83% (76-88) for supramaximal T2-FLAIR resection (class 1). Associations between survival and extensive resection were evident after 3 years in astrocytomas, whereas survival curves separated after 6-8 years in oligodendrogliomas. The prognostic relevance of the four-tier classification was conserved in multivariable analyses, in 625 patients receiving first-line chemotherapy or radiotherapy (with or without chemotherapy), and in the external UCSF cohort of 381 patients with IDH-mutant grade 2 gliomas. Interpretation: The proposed RANO classification for extent of resection could serve as a tool for prognostic stratification. Although associations between survival and extensive surgery are evident sooner in patients with astrocytoma, supramaximal resection also translates into survival benefits for patients with oligodendrogliomas. Funding: None.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherLancet Pub. Group-
dc.relation.isPartOfLANCET ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHBrain Neoplasms* / classification-
dc.subject.MESHBrain Neoplasms* / genetics-
dc.subject.MESHBrain Neoplasms* / mortality-
dc.subject.MESHBrain Neoplasms* / pathology-
dc.subject.MESHBrain Neoplasms* / surgery-
dc.subject.MESHFemale-
dc.subject.MESHGlioma* / genetics-
dc.subject.MESHGlioma* / mortality-
dc.subject.MESHGlioma* / pathology-
dc.subject.MESHGlioma* / surgery-
dc.subject.MESHHumans-
dc.subject.MESHIsocitrate Dehydrogenase* / genetics-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMutation*-
dc.subject.MESHNeoplasm Grading-
dc.subject.MESHNeoplasm, Residual-
dc.subject.MESHNeurosurgical Procedures* / mortality-
dc.subject.MESHPrognosis-
dc.subject.MESHProgression-Free Survival-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHYoung Adult-
dc.titleA prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiology (영상의학교실)-
dc.contributor.googleauthorPhilipp Karschnia-
dc.contributor.googleauthorJacob S Young-
dc.contributor.googleauthorMaarten M J Wijnenga-
dc.contributor.googleauthorTommaso Sciortino-
dc.contributor.googleauthorNico Teske-
dc.contributor.googleauthorAlba Corell-
dc.contributor.googleauthorArthur Wagner-
dc.contributor.googleauthorGilbert Youssef-
dc.contributor.googleauthorYae Won Park-
dc.contributor.googleauthorLevin Häni-
dc.contributor.googleauthorStephanie T Jünger-
dc.contributor.googleauthorAntonio Dono-
dc.contributor.googleauthorFelix Ehret-
dc.contributor.googleauthorEduardo E Mendoza Mireles-
dc.contributor.googleauthorNicolas Neidert-
dc.contributor.googleauthorFrancesco Bruno-
dc.contributor.googleauthorChad A Tuchek-
dc.contributor.googleauthorThijs van der Vaart-
dc.contributor.googleauthorMarco Rossi-
dc.contributor.googleauthorMarco Conti Nibali-
dc.contributor.googleauthorLorenzo Gay-
dc.contributor.googleauthorAlfred Gramelt-
dc.contributor.googleauthorNitin Tandon-
dc.contributor.googleauthorSung Soo Ahn-
dc.contributor.googleauthorJong Hee Chang-
dc.contributor.googleauthorMichael Weller-
dc.contributor.googleauthorArnaud J P E Vincent-
dc.contributor.googleauthorRoland Goldbrunner-
dc.contributor.googleauthorDaniel P Cahill-
dc.contributor.googleauthorRaymond Y Huang-
dc.contributor.googleauthorAndreas Raabe-
dc.contributor.googleauthorBernhard Meyer-
dc.contributor.googleauthorJuergen Beck-
dc.contributor.googleauthorAnnette M Molinaro-
dc.contributor.googleauthorSusan M Chang-
dc.contributor.googleauthorMichael A Vogelbaum-
dc.contributor.googleauthorRoberta Rudà-
dc.contributor.googleauthorEinar O Vik-Mo-
dc.contributor.googleauthorJorg Dietrich-
dc.contributor.googleauthorYoshua Esquenazi-
dc.contributor.googleauthorStefan J Grau-
dc.contributor.googleauthorPatrick Y Wen-
dc.contributor.googleauthorAsgeir S Jakola-
dc.contributor.googleauthorOliver Schnell-
dc.contributor.googleauthorLorenzo Bello-
dc.contributor.googleauthorMartin J van den Bent-
dc.contributor.googleauthorShawn Hervey-Jumper-
dc.contributor.googleauthorMitchel S Berger-
dc.contributor.googleauthorJoerg-Christian Tonn-
dc.identifier.doi10.1016/S1470-2045(25)00534-0-
dc.contributor.localIdA05330-
dc.contributor.localIdA03470-
dc.relation.journalcodeJ02154-
dc.identifier.eissn1474-5488-
dc.identifier.pmid41308678-
dc.contributor.alternativeNamePark, Yae-Won-
dc.contributor.affiliatedAuthor박예원-
dc.contributor.affiliatedAuthor장종희-
dc.citation.volume26-
dc.citation.number12-
dc.citation.startPage1638-
dc.citation.endPage1650-
dc.identifier.bibliographicCitationLANCET ONCOLOGY, Vol.26(12) : 1638-1650, 2025-12-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.